Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy-Reference-Cited by-同舟云学术

Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy

Published:2022-12-22 Issue:3 Volume:64 Page:347-348
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Pomykala Kelsey L.,Würker Marcus,Herrmann Ken

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference10 articles.

1. Hayes A . Last mile: what it means in reaching customers. Investopedia website. https://www.investopedia.com/terms/l/lastmile.asp. Published May 5, 2022. Accessed November 7, 2022.

2. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

3. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis;Kim;Clin Nucl Med.,2018

4. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

5. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotheranostics Global Market and Future Developments;Seminars in Nuclear Medicine;2024-07

2. Differences and Common Ground in¹⁷⁷Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers;Journal of Nuclear Medicine;2024-01-18

3. Synthesis of ¹⁷⁷Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics;Inorganic Chemistry;2023-08-09

4. The¹⁷⁷Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition;Journal of Nuclear Medicine;2023-03